Idiopathic Inflammatory Myopathies
45
18
23
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.2%
1 terminated out of 45 trials
88.9%
+2.3% vs benchmark
4%
2 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (45)
Biomarkers in Autoimmune Disease of Nervous System
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
A Study of AZD0120 in Autoimmune Diseases
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Study of Families With Twins or Siblings Discordant for Rheumatic Disorders
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
MTS109 in Patients With Refractory Autoimmune Diseases
Adult Autoimmune Myopathies (MAIA)
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders
Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101